What is Pliant Therapeutics Inc Annual Net Profit?

Pliant Therapeutics Inc Annual Net Profit fell 30.35% in the last year to $210.3 M. Its sector's average net profit growth for the last fiscal year was -32.43%.

What is Pliant Therapeutics Inc Price to Earning Ratio?

Pliant Therapeutics Inc Price to Earning Ratio is -0.45, which is negative.

What is Pliant Therapeutics Inc Stock Price?

Pliant Therapeutics Inc Stock Price fell 89.78% and underperformed its sector by 98.85% in the past year.

What is Pliant Therapeutics Inc Quarterly Net profit?

Pliant Therapeutics Inc Quarterly Net profit fell 20.98% YoY to $49.73 M. Its sector's average net profit growth YoY for the quarter was -47.3%.

What is Pliant Therapeutics Inc Mutual Fund Holding?

Pliant Therapeutics Inc Mutual Fund Holding increased by 0.79% in the last quarter to 61.23.

What is Pliant Therapeutics Inc Institutional Holding?

Pliant Therapeutics Inc Institutional Holding decreased by 0.31% in the last quarter to 109.96.

How is the Pliant Therapeutics Inc today?

The Pliant Therapeutics Inc today is trading in the down by -1.90% at 1.55.

How has Pliant Therapeutics Inc performed historically?

The Pliant Therapeutics Inc is currently trading down -1.90% on an intraday basis in the past week the index rose 0.65%. The index has been down -88.25% in the past quarter and fell -89.78% in the past year. You can view this in the overview section.

Pliant Therapeutics Inc XNAS: PLRX

Pliant Therapeutics Inc Live Share Price Today, Share Analysis and Chart

Name: Pliant Therapeutics Inc: Is Infosys Ltd. worth buying?
Item: Pliant Therapeutics Inc
Rating: 0.92083325
Author: Trendlyne DVM scores

Download real time

1.55 -0.03 (-1.90%)

90.62% Fall from 52W High

3.9M XNAS Volume

XNAS 21 Mar, 2025 5:30 PM (EDT)

Pliant Therapeutics Inc Key Metrics

My Metrics

Default

Market Capitalization Below industry Median Unavailable in chosen country	94.9
PE TTM Negative PE TTM Unavailable in chosen country	-0.5
Price to Book Low in industry Unavailable in chosen country	0.3
Institutional holding current Qtr % High in industry Unavailable in chosen country	110
Operating Revenue growth TTM % Negative Operating Revenue growth TTM % Unavailable in chosen country	-100
Net Profit Qtr Growth YoY % Negative Net Profit Qtr Growth YoY % Unavailable in chosen country	-21
Net Profit TTM Growth % Negative Net Profit TTM Growth % Unavailable in chosen country	-30.4
Piotroski Score Below industry Median Unavailable in chosen country	1
Rel Perf vs Sector quarter% Unavailable in chosen country	-96.9

All financials are in USD Million and price data in USD

Not Eligible

Expensive Valuation

15.3 / 100

Technically Bearish

21.5 / 100

1Yr Price target upside is 2492%

11 analysts

Check Before You Buy

Check P/E Buy Sell Zone

This stock has negative PE

Pliant Therapeutics Inc Stock Price Analysis

Day Price Range -1.9% 1 Day return Unavailable in chosen country	1.6 (LTP) 1.51.7 LowHigh
Week Price Range 0.6% 1 Week return Unavailable in chosen country	1.6 (LTP) 1.51.8 LowHigh
Month Price Range -49.7% 1 Month return Unavailable in chosen country	1.6 (LTP) 1.33.5 LowHigh
52 Week Price Range -89.8% 1 Year return Unavailable in chosen country	1.6 (LTP) 1.316.5 LowHigh

View full Share Price History

Pliant Therapeutics Inc Live Price Chart

Switch to TradingView

Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Miss

Pliant Therapeutics Inc's Revenue was lower than average estimate 2 times in past 3 years

EPS forecast

QUARTER
ANNUAL

Current EPS

-4.1

Avg. Estimate

-4.1

Low Estimate

-5.2

High Estimate

-3.6

Current EPS

Avg. Estimate

Consensus Recommendation

13 ANALYST Recommendations

STRONG BUY

The consensus recommendation from 13 analysts for Pliant Therapeutics Inc is STRONG BUY

Forecaster is a Premium Feature

You need to upgrade your subscription plan to access this feature

Upgrade Now

Pliant Therapeutics Inc Stock Analysis

Pliant Therapeutics Inc stock analysis with key metrics, changes, and trends.

Pliant Therapeutics Inc Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Net Profit	$210.3 M	30.35%	negative	Annual Net Profit fell 30.35% in the last year to $210.3 M. Its sector's average net profit growth for the last fiscal year was -32.43%.
Price to Earning Ratio	-0.45	-	negative	Price to Earning Ratio is -0.45, which is negative.
Stock Price	$1.55	-89.78%	negative	Stock Price fell 89.78% and underperformed its sector by 98.85% in the past year.
Quarterly Net profit	$49.73 M	20.98%	negative	Quarterly Net profit fell 20.98% YoY to $49.73 M. Its sector's average net profit growth YoY for the quarter was -47.3%.
Mutual Fund Holding	61.23 %	0.79%	positive	Mutual Fund Holding increased by 0.79% in the last quarter to 61.23.
Institutional Holding	109.96 %	-0.31%	negative	Institutional Holding decreased by 0.31% in the last quarter to 109.96.

VIEW LESS

Loading data..

Pliant Therapeutics Inc - Company Profile

What does Pliant Therapeutics Inc do?

Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.

Pliant Therapeutics Inc Management structure

All Gross Remunerations are in USD

Dr. Bernard Coulie, M.B.A.,M.D.,PhD

Director, President, and Chief Executive Officer

2024

Gross Remuneration

Year

Dr. Keith Cummings, M.B.A.,M.D.

Chief Financial Officer

2024

Gross Remuneration

2024

Gross Remuneration

Year

Pliant Therapeutics Inc Live Share Price Today, Share Analysis and Chart

90.62% Fall from 52W High

Pliant Therapeutics Inc Key Metrics

Market Capitalization

PE TTM

Price to Book

Institutional holding current Qtr %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Piotroski Score

Rel Perf vs Sector quarter%

Market Capitalization

PE TTM

Price to Book

Institutional holding current Qtr %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Piotroski Score

Rel Perf vs Sector quarter%

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

Pliant Therapeutics Inc Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

Pliant Therapeutics Inc Live Price Chart

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Pliant Therapeutics Inc's Revenue was lower than average estimate 2 times in past 3 years

EPS forecast

Consensus Recommendation

The consensus recommendation from 13 analysts for Pliant Therapeutics Inc is STRONG BUY

Pliant Therapeutics Inc Stock Analysis

Pliant Therapeutics Inc stock analysis with key metrics, changes, and trends.

Annual Net Profit fell 30.35% in the last year to $210.3 M. Its sector's average net profit growth for the last fiscal year was -32.43%.

Price to Earning Ratio is -0.45, which is negative.

Stock Price fell 89.78% and underperformed its sector by 98.85% in the past year.

Quarterly Net profit fell 20.98% YoY to $49.73 M. Its sector's average net profit growth YoY for the quarter was -47.3%.

Mutual Fund Holding increased by 0.79% in the last quarter to 61.23.

Institutional Holding decreased by 0.31% in the last quarter to 109.96.

Pliant Therapeutics Inc - Company Profile

What does Pliant Therapeutics Inc do?

Pliant Therapeutics Inc Management structure

Dr. Bernard Coulie, M.B.A.,M.D.,PhD

Director, President, and Chief Executive Officer

Dr. Keith Cummings, M.B.A.,M.D.

Chief Financial Officer

Pliant Therapeutics Inc Board of directors

Mr. Steven E. Krognes

Independent Director

Dr. Hoyoung Huh,M.D.,PhD

Chairman of the Board and Lead Independent Directo

Mr. David E.I. Pyott, M.B.A.,M.D.

Independent Director

Mr. Thomas A. McCourt

Independent Director

Ms. Gayle A. Crowell

Independent Director

Dr. Suzanne L. Bruhn, PhD

Independent Director

Pliant Therapeutics Inc FAQ

How is Pliant Therapeutics Inc today?

Pliant Therapeutics Inc today is trading in the red, and is down by -1.90% at 1.55.

How has Pliant Therapeutics Inc performed historically?

Pliant Therapeutics Inc is currently trading down -1.90% on an intraday basis. In the past week the stock rose 0.65%. stock has been down -88.25% in the past quarter and fell -89.78% in the past year. You can view this in the overview section.